Bajaj Healthcare Limited

5%

iroze Jeejeebhoy Towers Dalal Street Mumbai — 400 001 National Stock Exchange of India Limited 5% Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : 539872

24.78%

ished formulations & Nutraceuticals. Revenue Segment B2B (FY 21-22) Domestic v/s Export Sales 24.78% Breakup of Revenue 1% 13% Financial Management Long term CRISIL BBB/ Positive: Short term CRIS

1%

euticals. Revenue Segment B2B (FY 21-22) Domestic v/s Export Sales 24.78% Breakup of Revenue 1% 13% Financial Management Long term CRISIL BBB/ Positive: Short term CRISILA3+ Headcount ( Pay

13%

cals. Revenue Segment B2B (FY 21-22) Domestic v/s Export Sales 24.78% Breakup of Revenue 1% 13% Financial Management Long term CRISIL BBB/ Positive: Short term CRISILA3+ Headcount ( Payroll

75.22%

itive: Short term CRISILA3+ Headcount ( Payroll & Contract ) 31st March, 2022 1600+ Employees 75.22% 86% Export Local APIs Formulations Others Where we Are? Countries we Export Market Informat

86%

hort term CRISILA3+ Headcount ( Payroll & Contract ) 31st March, 2022 1600+ Employees 75.22% 86% Export Local APIs Formulations Others Where we Are? Countries we Export Market Information

₹9,394.50

e listed and actively traded on the BSE and NSE. The Company enjoyed a Market capitalisation of ₹9,394.50 Mn as on 31st March, 2022. Focus on off – patented APIs Strong R&D Team Amount Spent on R&D i

₹32.28

st March, 2022. Focus on off – patented APIs Strong R&D Team Amount Spent on R&D in FY22 : ₹32.28 Mn 03 BAJAJ HEALTHCARE LIMITEDwww.bajajhealth.com Corporate Overview Active Pharmaceutical I

rs. 05

ieve excellence in our products and services and to build long term relationships with our customers. 05 BAJAJ HEALTHCARE LIMITEDwww.bajajhealth.com Key Milestones Incorporated company and establishmen

615 MT

e Panoli plant, Bharuch after reopening Active Pharma Ingredients Intermediaries Formulations 615 MT/p.m. 33 MT/p.m. 92 MN pcs/p.m. - 61 MT/p.m. 111 MT/p.m - - - 4 MT/p.m Total Capacity 730

33 MT

t, Bharuch after reopening Active Pharma Ingredients Intermediaries Formulations 615 MT/p.m. 33 MT/p.m. 92 MN pcs/p.m. - 61 MT/p.m. 111 MT/p.m - - - 4 MT/p.m Total Capacity 730 MT/p.m. 94

61 MT

ctive Pharma Ingredients Intermediaries Formulations 615 MT/p.m. 33 MT/p.m. 92 MN pcs/p.m. - 61 MT/p.m. 111 MT/p.m - - - 4 MT/p.m Total Capacity 730 MT/p.m. 94 MT/p.m. 92 MN pcs/p.m. *Note

“The market is expected to reach $2135.18 billion in 2026 at a CAGR of 7.7%.* *Source:https://www.globenewswire.com/en/news-release/2022/03/04/2396935/0/en/Pharmaceuticals-Global- Market Report-2022.html Indian Pharma Market India’s domestic pharmaceutical market is at US$ 42 billion in 2021 and likely to reach US$ 65 billion by 2024 and further expand to reach ~US$ 120- 130 billion by 2030.”

“The global ascorbic acid market size is expected to reach USD 1.61 Billion in 2028 at a CAGR of 5.0% during the forecast period, according to the latest report by Reports and Data.”

“MR in its latest study has predicted impressive growth on card for the market during its forecast period of 2018 and 2028.”

“The market is poised to expand at an impressive 8% CAGR through 2028.”

“Chlorhexidine Gluconate Solution Market size is forecast to reach $196.1 million by 2026, after growing at a CAGR of 3.2% during 2021-2026.”

“Data Bridge Market Research analyses that the theobromine powder market will witness a CAGR of 3.50% for the forecast period of 2021-2028.”

“29 BAJAJ HEALTHCARE LIMITEDwww.bajajhealth.com Strategy & Guidance Business Strategies Forward Guidance Focus to launch 3-4 new products, through reverse engineering in APIs by FY2023 To focus on increasing global footprints for APIs like, Vildagliptin, Sitagliptin, Deferasirox, Chlorhexidine Gluconate, Fosfomycin, Theobromine & Octenidine Hydrochloride To increase the share of formulation business by adding more Finished Dosage formulations (FDF) & increasing the no.”

Manufacturing Plant of Finished Formulations

1

Intermediates

1

Each ml contains

1

Ascorbic Acid

1

Citicoline Sodium

1

Chlorhexidine Gluconate Solution

1

Global Theobromine Powder Market

1

Intermediates

Europe, USA, Australia, Africa, Middle East, South America, Zealand, Australia, New Srilanka, South East Asia, etc. BHL equity shares are listed and actively traded on the BSE and NSE. The Company enjoyed a Market capitalisation of ₹9,394.50 Mn as on 31st March, 2022. Focus on off – patented APIs Strong R&D Team Amount Spent on R&D in FY22 : ₹32.28 Mn 03 BAJAJ HEALTHCARE LIMITEDwww.bajajhealth.com Corporate Overview Active Pharmaceutical Ingredients (APIs) Intermediates Finished Dosage Formulation (FDFs) We focus on efficiently manufacturing high-quality and high value APIs in key therapeutic categories. We focus manufacturing intermediates which form a key input component for its API and FDF manufacturing, thereby ensuring a steady demand for our products. We focus on manufacturing tablets, capsules and powders which find application in key therapeutic segments. Product category Active Pharmaceutical Ingredients (APIs) and intermediates Key products Ascorbic Acid, CH Base and its Deri

Each ml contains

Ascorbic Acid I.P. 250mg Water of Injection I.P. q.s. Overage of Vitamin added to compensate loss on storage. 6 ml Ascorbic Acid Injection I.P VITAJAJ-C 1.5 gm/6 ml or Intravenous Use Only Any unused Portion must be Discarded within 4 hrs. Contains no Preservative Vitamin C is a potential therapeutic candidate, both for the treatment & amelioration of COVID-19 infection & as an adjunctive therapy in the critical care of COVID-19* Pharmacological Reports (2020) 72:1517–1528 https://doi.org/10.1007/s43440-020-00176-1 Amphotericin B Injection “DGJAJ” (2-Deoxy-D-Glucose) VITAJAJ- C Injection injection is used Amphotericin B treat serious and potentially to life-threatening infections. fungal Amphotericin B injection is in a class of medications called antifungals. It is used for treating Mucormycosis (Black fungus) infections in Covid-19 patients. It works by slowing the growth of fungi that cause infection. Deoxy-D-glucose (2-DG) is a glucose analogue, which has the 2-hydroxyl group repla

Ascorbic Acid

The global ascorbic acid market size is expected to reach USD 1.61 Billion in 2028 at a CAGR of 5.0% during the forecast period, according to the latest report by Reports and Data. Steady market revenue growth can be attributed to increasing use of ascorbic acid as a preservative and natural supplement in bakery items and canned products, rising popularity of anti-aging serums, creams, and other cosmetic products having vitamin C, intravenous administration of ascorbic acid to treat chronic conditions, for and rising consumer preference dietary vitamin supplements. *Source:https://www.biospace.com/article/ascorbic- acid-market-size-to-reach-usd-1-61-billion-in-2028-says-re- ports-and-data/ 19

Citicoline Sodium

The global citicoline market registered 8% year on year growth in 2018, which is expected to rise further by 2028. Rising cases of glaucoma and retinal neuro- degradation among geriatric population will remain a chief growth driver. Fact. MR in its latest study has predicted impressive growth on card for the market during its forecast period of 2018 and 2028. The market is poised to expand at an impressive 8% CAGR through 2028.

Chlorhexidine Gluconate Solution

Chlorhexidine Gluconate Solution Market size is forecast to reach $196.1 million by 2026, after growing at a CAGR of 3.2% during 2021-2026. It is a biguanide compound that is used in the antiseptic agent for tropical antibacterial activity. Chlorhexidine Gluconate is an aqueous solution that is widely used in surgical hand scrub. *Source:https://www.biospace.com/article/citicoline- market-to-surpass-us-500-mn-in-response-to-rising- incidence-of-alzheimer-s-disease-and-glaucoma-in- geriatric-population-fact-mr/ *S ource:https://www.industryarc.com/Research/ Chlorhexidine-Gluconate-Solution-Market-Research- 5 0 1 6 7 0 # : ~ : t e x t = C h l o r h e x i d i n e % 2 0 G l u co n a te % 2 0 Solution%20Market%20size,3.2%25%20during%20 2021%2D2026.

Global Theobromine Powder Market

Data Bridge Market Research analyses that the theobromine powder market will witness a CAGR of 3.50% for the forecast period of 2021-2028. Growth in the demand for theobromine powder especially in the developing economies such as India and China, growing use of theobromine powder for a wide range of end user applications such as food and industrial beverages, pharmaceutical, and other end user applications, and surge in industrialization especially in the developing countries are the major factors attributable to the growth of the theobromine powder market. Therefore, the theobromine powder market value, which was USD 2300 million in 2020, would stand tall by USD 3028.66 million by 2028. Source:https://www.databridgemarketresearch.com/ reports/Global-Theobromine-Powder-Market BAJAJ HEALTHCARE LIMITEDwww.bajajhealth.com Clientele: Domestic and Global API top Clients - Domestic Sun Pharma Ltd. Pfizer Ltd. Hindustan Unilever Abbott Healthcare P. Ltd. Glaxo Smith Kline plc API top Clients